💊FDA PHARMA TODAY
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
– Global phase 2 study will evaluate efficacy and safety of DS-8201 in patients with HER2-expressing advanced colorectal cancer who have received at least two prior lines of standard treatment
– Currently no HER2-targeting therapy is approved for patients with HER2-expressing colorectal cancer
– Following initiation of pivotal phase 2 studies in HER2-positive breast cancer and gastric cancer, the initiation of a third phase 2 study in colorectal cancer demonstrates commitment of Daiichi Sankyo to accelerating the development of DS-8201 across multiple HER2-expressing tumors
https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006822.html